Altisource Portfolio Solutions is a marketplace and transaction solutions provider for the real estate, mortgage and consumer debt industries. Co. has three reportable segments: mortgage services, which provides asset management services, origination services, insurance services, property valuation services, and default management services; financial services, which provides collection services primarily to debt originators and servicers and customer relationship management services primarily to the utility, insurance and hotel industries; and technology services, which provides software and data analytics solutions and information technology infrastructure management services.

Appian provides low-code automation platform that accelerates the creation of business applications, enabling its customers to automate their business. The company's platform automates the creation of forms, data flows, records, reports and other software elements that would otherwise need to be manually coded. The company'snSelf-Assembling Interface Layer technology ensures that applications developed on its platform can be deployed across a range of mobile and desktop devices, including desktop web browsers, tablets and mobile phones. The company's platform can be deployed in the cloud or on-premises, with organizations able to access the same functionality and data sources in various cases.

Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of product candidates against validated molecular targets in indications of unmet medical need. The company's main product candidate, AT-007, is a central nervous system, penetrant AR inhibitor (ARI) that the company is developing for the treatment of galactosemia, a rare pediatric metabolic disease that affects how the body processes a simple sugar called galactose. The company's second product candidate, AT-001, is an ARI with systemic exposure and peripheral nerve permeability that the company is developing for the treatment of diabetic cardiomyopathy, a fatal fibrosis of the heart.

Axsome Therapeutics is a clinical-stage biopharmaceutical company developing therapies for the management of central nervous system (CNS) disorders. The company's CNS product candidates includes: AXS-05, which is for the treatment resistant depression and in agitation associated with Alzheimer's disease; AXS-07, which is initially being developed for the acute treatment of migraine; AXS-09, which is being developed for CNS disorders; AXS-12, which is in development for the treatment of narcolepsy; AXS-02, which is being developed for the treatment of knee osteoarthritis and chronic low back pain; and AXS-06, which is being developed for the treatment of osteoarthritis and rheumatoid arthritis.

BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The company's commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.

Chiasma is a clinical-stage biopharmaceutical company focused on improving the lives of patients who face challenges related with their existing treatments for diseases. The company is evaluating oral octreotide capsules, conditionally trade-named MYCAPSSA, its sole Transient Permeability Enhancer platform-based clinical product candidate, in clinical trials in adult patients for the treatment of acromegaly to potentially support regulatory approval in the United States and European Union. The company is also conducting a clinical trial, referred to as MPOWERED, of oral octreotide capsules for the maintenance treatment of adult patients with acromegaly to support regulatory approval in the European Union.

Editas Medicine is a clinical stage genome editing company focused on developing genomic medicines to treat a range of serious diseases. The company has developed a proprietary genome editing platform based on clustered, regularly interspaced, short palindromic repeats (CRISPR) technology. The company is developing both in vivo CRISPR medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body, and engineered cell medicines, in which cells are edited with the company's technology and then administered to the patient. In ocular diseases, the company's program is designed to address a specific genetic form of retinal degeneration called Leber congenital amaurosis 10.

The ExOne is a provider of three-dimensional (3D) printing machines and 3D printed and other products, materials and services to industrial customers. The company's business primarily consists of manufacturing and selling 3D printing machines and printing products. The company provides pre-production collaboration and print products for customers through its network of production service centers and ExOne adoption centers. The company also supplies the associated materials, including consumables and replacement parts, and other services, including training and technical support that is necessary for purchasers of the company's 3D printing machines to print products.

Impinj enables wireless connectivity for everyday items, delivering each items' identity, location and authenticity to business and consumer applications. The company's platform comprises endpoint integrated circuits, or ICs, connectivity and software that together deliver item data to business and consumer applications. The company's platform spans endpoints, connectivity and software and provides wireless item connectivity and information delivery. The company sells endpoint ICs, reader ICs, reader modules, readers, gateways and software as well as provides development, service and license agreements.

Kellogg is engaged in the manufacture and marketing of ready-to-eat cereal and convenience foods. The company's principal products are snacks, such as crackers, savory snacks, toaster pastries, cereal bars, granola bars and bites; and convenience foods, such as, ready-to-eat cereals, frozen waffles, veggie foods and noodles. The company's snacks brands are marketed under brands such as Kellogg's, Cheez-It, Pringles, Austin, Parati, and RXBAR. The company's cereals and cereal bars are generally marketed under the Kellogg's name, with some under the Kashi and Bear Naked brands. The company's frozen foods are marketed under the Eggo and Morningstar Farms brands.

Lexicon Pharmaceuticals is a biopharmaceutical company. The company is commercializing XERMELO? (telotristat ethyl), an orally-delivered small molecule drug for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. The company is developing Zynquista? (sotagliflozin), an orally-delivered small molecule drug candidate, as a treatment for type 1 2 diabetes. The company is also developing sotagliflozin as a treatment for type 2 diabetes, heart failure and chronic kidney disease. The company is developing LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain.

Ligand Pharmaceuticals is a biopharmaceutical company focused on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The company employs research technologies such as antibody discovery technologies, structure-based drug design, formulation science and liver targeted pro-drug technologies to assist companies in their work toward securing prescription drug and biologic approvals. The company's collaboration partners and licensees have programs in clinical development targeting cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney disease, among others.

Masimo is a medical technology company that develops, manufactures, and markets a variety of noninvasive monitoring technologies. The company provides its products to hospitals, emergency medical service providers, long-term care facilities, physician offices, veterinarians and consumers. The company's main business is Measure-through Motion and Low Perfusion? pulse oximetry monitoring, known as Masimo Signal Extraction Technology? pulse oximetry. The company's products offerings also includes noninvasive monitoring of blood constituents with an optical signature, optical organ oximetry monitoring, electrical brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring.

NRG Energy is an energy company. The company produces and sells electricity and related products and services in primary power markets in the United States and Canada. The company sells energy, services, and sustainable products and services directly to retail customers under the names NRG, Reliant, Green Mountain Energy, Stream and XOOM Energy, as well as other brand names owned by the company The company's segments are: Retail, which includes retail energy, portable solar and battery products home services, and a variety of bundled products; and Generation, which includes plant operations, commercial operations, development, engineering and construction, asset management, energy services and other related functions.

Reata Pharmaceuticals is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapies. The company focuses on on small-molecule therapeutics with mechanisms of action for the treatment of diseases with few or no approved therapies. The company's key programs are in rare forms of chronic kidney disease (CKD) and a rare neurological disease. The company's key product candidates include bardoxolone methyl (bardoxolone) in patients with CKD caused by Alport syndrome and omaveloxolone in patients with a neurological disorder called Friedreich's ataxia. The company is developing RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases.

Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of diseases. The company's commercialized medicines and product candidates in development are designed to assist patients with eye disease, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and rare diseases. The company's products include: EYLEA (aflibercept) injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema; and Dupixent (dupilumab) injection, which is used for the treatment of adult patients with atopic dermatitis.

REGENXBIO is a clinical-stage biotechnology company. The company's product candidates include: RGX-314, which is being developed as a gene therapy for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other additional chronic retinal conditions which cause total or partial vision loss for patients in the U.S., Europe and Japan; RGX-121, which is for the treatment of Mucopolysaccharidosis Type II; RGX-111, which is for the treatment of Mucopolysaccharidosis Type I; and RGX-181, which is for the treatment of late infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is for the treatment of homozygous familial hypercholesterolemia.

RGC Resources is a holding company. Through its subsidiaries, the company is an energy services company primarily engaged in the sale and distribution of natural gas. The company's wholly owned subsidiaries include: Roanoke Gas Company (Roanoke Gas); Diversified Energy Company; and RGC Midstream, LLC (Midstream). Roanoke Gas is a natural gas utility, which distributes and sells natural gas to residential, commercial and industrial customers within its service areas in Roanoke, VA and the surrounding localities. Diversified Energy Company is inactive. Midstream is an investor in Mountain Valley Pipeline, LLC, which was created to construct and operate interstate natural gas pipelines.

SailPoint Technologies Holdings is a provider of enterprise identity governance solutions. The company's SailPoint Predictive Identity platform provides organizations with visibility into who has access to which resources, who should have access to those resources, and how that access is being used. The company delivers an integrated set of solutions to address identity governance challenges for enterprises. The company's products include: IdentityIQ, which is an on-premises identity governance solution; IdentityNow, which is a cloud-based, multi-tenant identity governance platform; and IdentityAI, which is a multi-tenant artificial intelligence and machine learning software as a service subscription offering.

Splunk provides software solutions that enable users to investigate, monitor, analyze and act on machine data. The company's main product is Splunk Enterprise, a machine data platform, comprised of collection, indexing, search, reporting, analysis, alerting, monitoring and data management capabilities. The company's Splunk Cloud delivers the capabilities of Splunk Enterprise as a service, while Splunk Light provides log search and analysis for information technology environments. The company also provides services that include maintenance and customer support, training services to its customers and channel partners, as well as consulting and implementation services to customers through its services team.

Sunnova Energy International is a residential solar and energy storage service provider. The company offers solar battery storage units, as well as maintenance, monitoring, and management services. The company serves customers in the United States and Northern Mariana Islands.

Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems. The company's main solar service offerings are provided through its lease and power purchase agreements, which it refers to as its Customer Agreements. While homeowners have the option to purchase a solar energy system outright from the company, a majority of its customers choose to buy solar as a service through its Customer Agreements. With its solar service offerings, the company installs solar energy systems on its customers' homes and provides them the solar power produced by those systems. In addition, the company monitors, maintains and insures the system during the term of the contract.

Tandem Diabetes Care is a medical device company engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The company primarily focuses on the t:slim X2 Insulin Delivery System, or t:slim X2, the company's key pump platform that is capable of remote feature updates and designed to display continuous glucose monitoring sensor information directly on the pump home screen. In addition to selling insulin pumps, the company sells disposable products that are used together with the pumps and are replaced every few days, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to a user's body.

Venus Concept is a medical technology company developing and commercializing a robotic device, the ARTAS? System, that assists physicians in performing tasks that are a part of a follicular unit extraction surgery. The ARTAS? System includes the ARTAS Hair Studio application, a three-dimensional patient consultation tool that enables a physician to create a simulated hair transplant model for use in patient consultations. The ARTAS? System is comprised of the patient chair, the cart, which includes the robotic arm, vision system, artificial intelligence algorithms and a series of proprietary end effectors, which are the various devices at the end of the robotic arm.